AGN : Summary for Allergan plc Ordinary Shares - Yahoo Finance

We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. Markets closed

Allergan plc (AGN)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
188.47 -1.26 (-0.66%)
At close: 4:01 PM EST

187.65 -0.82 ( -0.44% )
After hours: 7:57 PM EST

People also watch :
BIIB CELG VRX GILD REGN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close 189.73
Open 188.93
Bid 188.00 x 100
Ask 188.90 x 400
Day's Range 185.70 - 191.00
52 Week Range 184.50 - 317.48
Volume 7,569,122
Avg. Volume 4,784,556
Market Cap 70.69B
Beta 1.09
PE Ratio (TTM) 5.29
EPS (TTM) 35.66
Earnings Date Feb 17, 2017
Dividend & Yield 2.80 (1.46%)
Ex-Dividend Date N/A
1y Target Est 264.84
Trade prices are not sourced from all markets
  • Trump Warns Investors "I'm Going To Bring Down Drug Prices"
    Motley Fool yesterday

    Trump Warns Investors "I'm Going To Bring Down Drug Prices"

    President-elect Donald Trump took aim at drug developers in a recent Time magazine interview and as a result, biopharma stocks are selling off.

  • Biotech analyst: Republicans will protect drug companies from Trump
    Business Insider yesterday

    Biotech analyst: Republicans will protect drug companies from Trump

    Drugmaker shares were reeling on Wednesday after president elect Donald Trump addressed drug...

  • Teva Pharmaceutical Industries Ltd (ADR) (TEVA)’s End-Of-Year Switch Of Generics CEO Surprises Investors
    Insider Monkey yesterday

    Teva Pharmaceutical Industries Ltd (ADR) (TEVA)’s End-Of-Year Switch Of Generics CEO Surprises Investors

    Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shareholders were treated to an unpleasant surprise by generics CEO Siggi Olafsson, who is said to be jumping ship. The move has also scared off investors and sent Teva shares south. But apparently, analysts were not puzzled by the news that Olafsson was turning the reins over to Dipankar […]

  • Barrons.com yesterday

    Don't Expect Allergan To Rebound In 2017

    Piper Jaffray’s David Amsellem and his team take a look at Allergan (AGN) Wednesday, and they aren’t optimistic about the stock’s prospects in 2017. Amesellem writes that data from retail prescription volumes across Allergan’sU.S. commercial portfolio reinforced their concerns about Allergan’s business. As such, he writes that he doesn’t think Allergan is poised for a rebound, and the shares valuation reflect the Street’s overly rosy growth expectations.

  • Investopedia 2 days ago

    Piper Jaffray Negative On Allergan (AGN)

    Piper Jaffray issued a Negative report on AGN this morning noting the business is not likely to see a rebound.

  • Teva shares drop after key departure in generics business
    CNBC 2 days ago

    Teva shares drop after key departure in generics business

    Shares of Teva dropped more than 5 percent Tuesday after the company announced the head of its global generic medicine group will step down.

  • 5 Best Large-Caps To Buy According To This Billionaire
    Insider Monkey 2 days ago

    5 Best Large-Caps To Buy According To This Billionaire

    Billionaire John Griffin founded Blue Ridge Capital 20 years ago, after working as Julian Robertson’s number two for years. The “Tiger Cub” is a value-oriented investor who has proven quite successful over time. As per Insider Monkey’s data, Mr. Griffin’s long equity stakes returned an average of 0.76% per month between 1999 and 2012 – […]

  • TheStreet.com 3 days ago

    Questions Mount at Teva as Generics Head Quits Without Explanation

    Siggi Olfasson is poised to step down as president and CEO of Teva's global generic medicines group by the end the first quarter of 2017.

  • Health care sector suffers: Time to buy the dip?
    CNBC Videos 7 hours ago

    Health care sector suffers: Time to buy the dip?

    Chris Retzler, Needham Growth Fund, and Ronny Gal, Sanford C. Bernstein, discuss buying opportunities amid health care's underperformance. With CNBC's Mike Santoli and Stephanie Link, TIAA Global Asset Management.

  • Drug pressure deja vu?
    CNBC Videos yesterday

    Drug pressure deja vu?

    CNBC's Meg Tirrell reports on which names in biotech were hit hardest last year by Hillary Clinton's tweet calling price gouging "outrageous."